Targeted Drug Therapy for Lymphoma 2023
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 180
Special Issue Editors
Interests: lymphoma; mantle cell lymphoma; cancer biology; drug resistance
Special Issue Information
Dear Colleagues,
Cancer therapy overall has substantially evolved in recent years and so has lymphoma treatment. New drugs, such as small molecules, have emerged and changed not only the landscape of treatment in hematology but also the prognosis for many patients in the past decade. In addition, the immunotherapy, such as CAR T cells or bispecific antibodies, are now changing the treatment landscape in lymphoma and will have a strong impact on therapeutic success. This progress led to the design of treatments that are more effective and this precision medicine often has fever adverse side effects than conventional therapies.
Nevertheless, lymphomas are very diverse and treatment response, as well as reasons for drug resistance and/or relapse are very distinct. Therefore, targeted options for specific lymphomas and individual patients become more and more relevant.
In this Special Issue “Targeted Drug Therapy for Lymphoma 2023” we want to highlight new lymphoma therapy options, targets, drugs, and opinions in this eminent field of research.
Dr. Hilka Rauert-Wunderlich
Dr. Johannes Duell
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B- and T-cell lymphomas
- drug resistance
- immunotherapy
- microenvironment
